Armata Pharmaceuticals Depreciation & Amortization Growth & History (ARMP)
Armata Pharmaceuticals's depreciation and amortization was $1.5M for fiscal 2025.
View full Armata Pharmaceuticals company overviewArmata Pharmaceuticals annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.5M | $206,000 | +15.55% |
| 2024 | 2024-12-31 | $1.3M | $353,000 | +36.32% |
| 2023 | 2023-12-31 | $972,000 | $80,000 | +8.97% |
| 2022 | 2022-12-31 | $892,000 | −$277,000 | −23.70% |
| 2021 | 2021-12-31 | $1.2M | $55,000 | +4.94% |
| 2020 | 2020-12-31 | $1.1M | −$237,000 | −17.54% |
| 2019 | 2019-12-31 | $1.4M | −$31,000 | −2.24% |
| 2018 | 2018-12-31 | $1.4M | $1.0M | +269.52% |
| 2017 | 2017-12-31 | $374,000 | $5,000 | +1.36% |
| 2016 | 2016-12-31 | $369,000 | $39,000 | +11.82% |
| 2015 | 2015-12-31 | $330,000 | $172,000 | +108.86% |
| 2014 | 2014-12-31 | $158,000 | $45,000 | +39.82% |
| 2013 | 2013-12-31 | $113,000 | — | — |
Armata Pharmaceuticals quarterly depreciation and amortization
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $500,000 | $134,000 | +36.61% |
| Q1 2026 | 2026-03-31 | $457,000 | $80,000 | +21.22% |
| Q4 2025 | 2025-12-31 | $418,000 | — | — |
| Q3 2025 | 2025-09-30 | $370,000 | $57,000 | +18.21% |
| Q2 2025 | 2025-06-30 | $366,000 | $51,000 | +16.19% |
| Q1 2025 | 2025-03-31 | $377,000 | $60,000 | +18.93% |
| Q3 2024 | 2024-09-30 | $313,000 | $92,000 | +41.63% |
| Q2 2024 | 2024-06-30 | $315,000 | $87,000 | +38.16% |
| Q1 2024 | 2024-03-31 | $317,000 | $87,000 | +37.83% |
| Q3 2023 | 2023-09-30 | $221,000 | $21,000 | +10.50% |
| Q2 2023 | 2023-06-30 | $228,000 | $28,000 | +14.00% |
| Q1 2023 | 2023-03-31 | $230,000 | $4,000 | +1.77% |
| Q3 2022 | 2022-09-30 | $200,000 | −$100,000 | −33.33% |
| Q2 2022 | 2022-06-30 | $200,000 | −$100,000 | −33.33% |
| Q1 2022 | 2022-03-31 | $226,000 | −$55,000 | −19.57% |
| Q3 2021 | 2021-09-30 | $300,000 | $0 | 0.00% |
| Q2 2021 | 2021-06-30 | $300,000 | $0 | 0.00% |
| Q1 2021 | 2021-03-31 | $281,000 | −$14,000 | −4.75% |
| Q3 2020 | 2020-09-30 | $300,000 | −$100,000 | −25.00% |
| Q2 2020 | 2020-06-30 | $300,000 | −$35,000 | −10.45% |
| Q1 2020 | 2020-03-31 | $295,000 | −$61,000 | −17.13% |
| Q3 2019 | 2019-09-30 | $400,000 | $56,000 | +16.28% |
| Q2 2019 | 2019-06-30 | $335,000 | −$73,000 | −17.89% |
| Q1 2019 · Mar 31 | 2019-03-31 | $356,000 | $259,000 | +267.01% |
| Q3 2018 | 2018-09-30 | $344,000 | $251,000 | +269.89% |
| Q2 2018 | 2018-06-30 | $408,000 | $316,000 | +343.48% |
| Q1 2018 · Mar 31 | 2018-03-31 | $97,000 | $4,000 | +4.30% |
| Q3 2017 | 2017-09-30 | $93,000 | −$2,000 | −2.11% |
| Q2 2017 | 2017-06-30 | $92,000 | $0 | 0.00% |
| Q1 2017 | 2017-03-31 | $93,000 | $12,000 | +14.81% |
| Q3 2016 | 2016-09-30 | $95,000 | −$13,000 | −12.04% |
| Q2 2016 | 2016-06-30 | $92,000 | $26,000 | +39.39% |
| Q1 2016 | 2016-03-31 | $81,000 | $15,000 | +22.73% |
| Q3 2015 | 2015-09-30 | $108,000 | — | — |
| Q2 2015 | 2015-06-30 | $66,000 | −$9,000 | −12.00% |
| Q1 2015 | 2015-03-31 | $66,000 | $40,000 | +153.85% |
| Q2 2014 | 2014-06-30 | $75,000 | $51,000 | +212.50% |
| Q1 2014 | 2014-03-31 | $26,000 | $5,000 | +23.81% |
| Q3 2013 | 2013-09-30 | $29,000 | — | — |
| Q2 2013 | 2013-06-30 | $24,000 | — | — |
| Q1 2013 | 2013-03-31 | $21,000 | — | — |
Armata Pharmaceuticals depreciation and amortization trends
Over the last five fiscal years, Armata Pharmaceuticals's depreciation and amortization increased from $1.1M to $1.5M, a change of $417,000. The latest reported quarter, Q2 2026, shows $500,000.
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Armata Pharmaceuticals source filings ↗